Figures
- FIGURE 1.
The key pathways and classes of drugs that have been approved for the treatment of pulmonary arterial hypertension. These may also have benefits in patients with chronic thromboembolic pulmonary hypertension, although further research is necessary to establish this. NO: nitric oxide; sGC: soluble guanylate cyclise; cGMP: cyclic guanosine monophosphate; COX: cyclo-oxygenase; NOS: NO synthase; ECE: endothelin converting enzyme; AC: adenylate cyclase; cAMP: cyclic adenosine monophosphate; ET: endothelin; GMP: guanosine monophosphate; PDE: phosphodiesterase; PH: pulmonary hypertension. Reproduced from [13] with permission from the publisher.
- FIGURE 2.
The embolic hypothesis of chronic thromboembolic pulmonary hypertension (CTEPH). VTE: venous thromboembolism; PE: pulmonary embolism.
